Systems, methods, and/or apparatuses may be operative to perform a dialysis process that includes a displacer infusion process. In one embodiment, a method for determining a displacer compound may include constructing a plurality of target protein quantitative structure-activity relationship (QSAR) models, one for each of the plurality of binding sites, analyzing a set of candidate compounds using the plurality of QSAR models to determine a set of at least one potential compound with an affinity for binding to each of the plurality of binding sites, and selecting at least one displacer compound from the set of at least one potential compound. Other embodiments are described.

Systems, methods, and/or apparatuses may be operative to perform a dialysis process that includes a displacer infusion process. The dialysis machine may include at least one processor and a memory coupled to the at least one processor, the memory comprising instructions that, when executed by the processor, may cause the at least one processor to access dialysis information for a dialysis process performed by a dialysis machine, the dialysis information indicating a target substance to be displaced from a binding compound by a displacer, and determine an infusion profile for infusing the displacer into a patient during a displacer infusion process of the dialysis process, the infusion profile determined based on the dialysis information and an infusion constraint. Other embodiments are described.

The present disclosure relates to a dialysis apparatus comprising a membrane having at least one protein from the lipocalin family bound thereon. The disclosure further relates to methods of removing non-polar, hydrophobic and/or protein bound uremic toxins from a target subject utilizing the dialysis apparatus described herein as well as methods of extracorporeal detoxification.

The present disclosure relates to an artificial, extracorporeal system for supporting the function of the liver of a patient suffering from liver failure, which is characterized in that it comprises a first high-flux or high cut-off hollow fiber membrane dialyzer which is perfused on the lumen side with the patient's blood and wherein a buffered aqueous solution comprising human serum albumin is passed in a continuous flow through the filtrate space of said first dialyzer, a second hollow fiber membrane dialyzer which removes water-soluble substances from the dialysate of said first dialyzer, and a third, integrated hollow fiber membrane dialyzer which is perfused with the retentate of second hemodialyzer and which allows the passage of certain amounts of albumin over the membrane wall into the filtrate space which is populated with adsorbent material. The system can be used for the treatment of acute liver failure and acute-on-chronic liver failure.

The present invention generally relates to a process suitable for extracorporeal lung support. The process comprises contacting blood with a dialysis liquid separated by a semipermeable membrane. Oxygen is introduced into blood and/or into the dialysis liquid prior to contacting blood and dialysis liquid being separated by the semipermeable membrane. The process is versatile and allows for blood oxygenation as well as removal of at least one undesired substance occurring in the blood, selected from carbon dioxide, bicarbonate and hydrogen cations, from blood. Thereby, the present invention takes advantage of the Haldane effect in the extracorporeal contacting step. The undesired substance can be efficiently transported across a semipermeable membrane to the dialysis liquid. In contrast to extracorporeal carbon dioxide removal methods of the prior art (ECCCbR), the present invention employs a versatile dialysis liquid that allows to adjust the pH and buffering capacity of the dialysis liquid, to add fluids to the dialysis liquid and/or to the blood and to remove substances from the blood in the extracorporeal circuit, depending on the conditions and needs. The present invention also provides regeneration and recycling of the dialysis liquid, and thus for its repeated use. The present invention is suitable for treating human or animal subjects suffering from lung failure or lung disorders.

Provided are methods and arrangements wherein gases are removed via semipermeable membranes from aqueous, optionally complex biological substance mixtures, by dialysis in an aqueous medium. Special carrier molecules for gases are included in the dialysate that are regenerated in the dialysate circuit so that they can be used for further gas exchange cycles on the membrane.

Systems, methods, and/or apparatuses may be operative to perform a dialysis process that includes a displacer infusion process. The dialysis machine may include at least one processor and a memory coupled to the at least one processor, the memory comprising instructions that, when executed by the processor, may cause the at least one processor to access dialysis information for a dialysis process performed by a dialysis machine, the dialysis information indicating a target substance to be displaced from a binding compound by a displacer, and determine an infusion profile for infusing the displacer into a patient during a displacer infusion process of the dialysis process, the infusion profile determined based on the dialysis information and an infusion constraint. Other embodiments are described.

Compounds, systems, kits, methods, and/or apparatuses may be operative to reduce amyloid beta (Aβ) peptide in a patient, including a central nervous system (CNS) of the patient and/or a periphery (non-CNS portion) of the patient. In some embodiments, a displacer fluid comprising a Aβ displacer may be introduced to the patient to bind to a blood protein, such as albumin, that binds Aβ (for instance, Aβ peptide or non-plaque Aβ) in the patient periphery. Binding of the displacer to the blood protein may facilitate more free Aβ peptide (for instance, Aβ monomers) in the periphery for clearance via natural processes, such as through the liver or kidneys, and/or artificial processes, such as dialysis. Increased removal of the free Aβ peptide in the periphery may ultimately lead to less Aβ peptide in the CNS, which may decrease Aβ plaque formation in Alzheimer's Disease (AD) patients. Other embodiments are described.

The present invention relates to the field of medical devices, more particularly the field of devices for extracting circulating molecules from the blood of a mammal, and their therapeutic uses, in particular in treating sepsis, cytokine release syndrome and/or any other form of systemic inflammatory response or cytokine shock, caused by bacterial, parasitic, fungal or viral infections, in particular caused by a viral infection, for example coronaviruses with human respiratory tract tropism.

According to some embodiments, a system may treat blood outside the body of a patient. The system may include one or more pumps configured to pump blood in a fluid flow path at a collective rate over 4 liters per minute. The system may include one or more heat exchangers operable to heat at least a portion of the blood to a temperature of at least 42 degrees Celsius and to allow the blood to cool one or more degrees following heating. The system may include one or more albumin dialysis modules configured to perform albumin dialysis on at least a portion of the blood at least after the one or more heat exchangers allow the blood to cool one or more degrees.